Top

Published in:

Open Access 01-12-2018 | Original research

Structural studies on radiopharmaceutical DOTA-minigastrin analogue (CP04) complexes and their interaction with CCK2 receptor

Authors: Piotr F. J. Lipiński, Piotr Garnuszek, Michał Maurin, Raphael Stoll, Nils Metzler-Nolte, Artur Wodyński, Jan Cz. Dobrowolski, Marta K. Dudek, Monika Orzełowska, Renata Mikołajczak

Published in: EJNMMI Research | Issue 1/2018

Abstract

Background

The cholecystokinin receptor subtype 2 (CCK-2R) is an important target for diagnostic imaging and targeted radionuclide therapy (TRNT) due to its overexpression in certain cancers (e.g., medullary thyroid carcinoma (MTC)), thus matching with a theranostic principle. Several peptide conjugates suitable for the TRNT of MTC have been synthesized, including a very promising minigastrin analogue DOTA-(DGlu)₆-Ala-Tyr-Gly-Trp-Met-Asp-Phe-NH₂ (CP04). In this contribution, we wanted to see whether CP04 binding affinity for CCK-2R is sensitive to the type of the complexed radiometal, as well as to get insights into the structure of CP04-CCK2R complex by molecular modeling.

Results

In vitro studies demonstrated that there is no significant difference in CCK-2R binding affinity and specific cellular uptake between the CP04 conjugates complexed with [⁶⁸Ga]Ga³⁺ or [¹⁷⁷Lu]Lu³⁺. In order to investigate the background of this observation, we proposed a binding model of CP04 with CCK-2R based on homology modeling and molecular docking. In this model, the C-terminal part of the molecule enters the cavity formed between the receptor helices, while the N-terminus (including DOTA and the metal) is located at the binding site outlet, exposed in large extent to the solvent. The radiometals do not influence the conformation of the molecule except for the direct neighborhood of the chelating moiety.

Conclusions

The model seems to be in agreement with much of structure-activity relationship (SAR) studies reported for cholecystokinin and for CCK-2R-targeting radiopharmaceuticals. It also explains relative insensitivity of CCK-2R affinity for the change of the metal. The proposed model partially fits the reported site-directed mutagenesis data.

Reubi JC, Waser B. Unexpected high incidence of cholecystokinin-B/gastrin receptors in human medullary thyroid carcinomas. Int J Cancer. 1996;67:644–7.CrossRefPubMed

Reubi JC, Schaer JC, Waser B. Cholecystokinin(CCK)-A and CCK-B/gastrin receptors in human tumors. Cancer Res. 1997;57:1377–86.PubMed

Reubi JC. CCK receptors in human neuroendocrine tumors: clinical implications. Scand J Clin Lab Invest. 2001;61:101–4.CrossRef

Aloj L, Aurilio M, Rinaldi V, D’ambrosio L, Tesauro D, Peitl PK, et al. Comparison of the binding and internalization properties of 12 DOTA-coupled and 111In-labelled CCK2/gastrin receptor binding peptides: a collaborative project under COST action BM0607. Eur J Nucl Med Mol Imaging Springer-Verlag. 2011;38:1417–25.CrossRef

Ocak M, Helbok A, Rangger C, Peitl PK, Nock BA, Morelli G, et al. Comparison of biological stability and metabolism of CCK2 receptor targeting peptides, a collaborative project under COST BM0607. Eur J Nucl Med Mol Imaging. 2011;38:1426–35.CrossRefPubMed

Laverman P, Joosten L, Eek A, Roosenburg S, Peitl PK, Maina T, et al. Comparative biodistribution of 12 111In-labelled gastrin/CCK2 receptor-targeting peptides. Eur J Nucl Med Mol Imaging. 2011;38:1410–6.CrossRefPubMedPubMedCentral

Kolenc Peitl P, Tamma M, Kroselj M, Braun F, Waser B, Reubi JC, et al. Stereochemistry of amino acid spacers determines the pharmacokinetics of 111In-DOTA-Minigastrin analogues for targeting the CCK2/gastrin receptor. Bioconjug Chem American Chemical Society. 2015;26:1113–9.CrossRef

Pawlak D, Rangger C, Kolenc Peitl P, Garnuszek P, Maurin M, Ihli L, et al. From preclinical development to clinical application: kit formulation for radiolabelling the minigastrin analogue CP04 with In-111 for a first-in-human clinical trial. Eur J Pharm Sci. 2016;85:1–9.CrossRefPubMedPubMedCentral

Maina T, Konijnenberg MW, Kolenc Peitl P, Garnuszek P, Nock BA, Kaloudi A, et al. Preclinical pharmacokinetics, biodistribution, radiation dosimetry and toxicity studies required for regulatory approval of a phase I clinical trial with 111In-CP04 in medullary thyroid carcinoma patients. Eur J Pharm Sci. 2016;91:236–42.CrossRefPubMedPubMedCentral

10.

Koumarianou E, Loktionova NS, Fellner M, Roesch F, Thews O, Pawlak D, et al. 44Sc-DOTA-BN[2-14]NH 2 in comparison to 68Ga-DOTA-BN[2-14]NH 2 in pre-clinical investigation. Is 44Sc a potential radionuclide for PET. Appl. Radiat. Isot. Elsevier. 2012;70:2669–76.CrossRef

11.

Fani M, Braun F, Waser B, Beetschen K, Cescato R, Erchegyi J, et al. Unexpected sensitivity of sst2 antagonists to N-terminal radiometal modifications. J Nucl Med. 2012;53:1481–9.CrossRefPubMed

12.

Roosenburg S, Laverman P, Joosten L. PET and SPECT imaging of a radio labeled minigastrin analogue conjugated with DOTA, NOTA, and NODAGA and labeled with Cu-64, Ga-68, and In-111. Mol Pharmaceutics. 2014;11:3930–7.

13.

Maurin M, Garnuszek P, Baran P, Pawlak D, Mikołajczak R. The radiometal makes a difference. Synthesis and preliminary characterisation of DOTA-minigastrin analogue complexes with Ga, Lu and y. Nucl Med Rev. 2015;18:51–5.CrossRef

14.

Aloj L, Caracò C, Panico M, Zannetti A, Del Vecchio S, Tesauro D, et al. In vitro and in vivo evaluation of 111In-DTPAGlu-G-CCK8 for cholecystokinin-B receptor imaging. J Nucl Med. 2004;45:485–94.PubMed

15.

Kaloudi A, Nock BA, Lymperis E, Krenning EP, de Jong M, Maina T. Improving the in vivo profile of minigastrin radiotracers: a comparative study involving the neutral endopeptidase inhibitor phosphoramidon. Cancer Biother Radiopharm. Mary Ann Liebert, Inc. 140 Huguenot Street, 3rd Floor New Rochelle, NY 10801 USA. 2016;31:20–8.CrossRefPubMed

16.

Kokoschka M, Bangert J-A, Stoll R, Sheldrick WS. Sequence-selective organoiridium DNA bis-intercalators with flexible dithiaalkane linker chains. Eur J Inorg Chem. 2010;2010:1507–15.CrossRef

17.

Nowaczyk M, Berghaus C, Stoll R, R?gner M, Yocum CF, Klinman JP, et al. Preliminary structural characterisation of the 33 kDa protein (PsbO) in solution studied by site-directed mutagenesis and NMR spectroscopy. Phys Chem. 2004;6:4878–81.

18.

Ali Nazif M, Bangert J-A, Ott I, Gust R, Stoll R, Sheldrick WS. Dinuclear organoiridium(III) mono- and bis-intercalators with rigid bridging ligands: synthesis, cytotoxicity and DNA binding. J Inorg Biochem. 2009;103:1405–14.CrossRefPubMed

19.

Glaves R, Baer M, Schreiner E, Stoll R, Marx D. Conformational dynamics of minimal elastin-like polypeptides: the role of proline revealed by molecular dynamics and nuclear magnetic resonance. ChemPhysChem. 2008;9:2759–65.CrossRefPubMed

20.

Stoll R, Voelter W, Holak TA. Conformation of thymosin beta 9 in water/fluoroalcohol solution determined by NMR spectroscopy. Biopolymers. 1997;41:623–34.CrossRefPubMed

21.

Song J, Markley JL. NMR chemical shift mapping of the binding site of a protein proteinase inhibitor: changes in the1H,13C and15N NMR chemical shifts of turkey ovomucoid third domain upon binding to bovine chymotrypsin A? J Mol Recognit. 2001;14:166–71.CrossRefPubMed

22.

Mestrelab Research. MestRe Nova. Santiago De Compostela; 2008. Available from: mestrelab.com/

23.

Biasini M, Bienert S, Waterhouse A, Arnold K, Studer G, Schmidt T, et al. SWISS-MODEL: modelling protein tertiary and quaternary structure using evolutionary information. Nucleic Acids Res. 2014;42:W252–8.CrossRefPubMedPubMedCentral

24.

Benkert P, Biasini M, Schwede T. Toward the estimation of the absolute quality of individual protein structure models. Bioinformatics. 2011;27:343–50.CrossRefPubMed

25.

Arnold K, Bordoli L, Kopp J, Schwede T. The SWISS-MODEL workspace: a web-based environment for protein structure homology modelling. Bioinformatics. 2006;22:195–201.CrossRefPubMed

26.

Trott O, Olson AJ. AutoDock Vina: improving the speed and accuracy of docking with a new scoring function, efficient optimization, and multithreading. J Comput Chem. 2010;31:455–61.PubMedPubMedCentral

27.

Miller LJ, Gao F. Structural basis of cholecystokinin receptor binding and regulation. Pharmacol Ther. 2008;119:83–95.CrossRefPubMedPubMedCentral

28.

Heppeler A, Froidevaux S, Mäcke HR, Jermann E, Béhé M, Powell P, et al. Radiometal-labelled macrocyclic chelator-derivatised somatostatin analogue with superb tumor-targeting properties and potential for receptor-mediated internal radiotherapy. Chem - a Eur J. 1999;5:1974–81.CrossRef

29.

Viola-Villegas N, Doyle RP. The coordination chemistry of 1,4,7,10-tetraazacyclododecane-N,N′,N″,N‴-tetra acetic acid (H4DOTA): structural overview and analyses on structure-stability relationships. Coord Chem Rev. 2009;253:1906–25.CrossRef

30.

Reubi JC, Waser B, Schaer JC, Laederach U, Erion J, Srinivasan A, et al. Unsulfated DTPA- and DOTA-CCK analogs as specific high-affinity ligands for CCK-B receptor-expressing human and rat tissues in vitro and in vivo. Eur J Nucl Med. 1998;25:481–90.CrossRefPubMed

31.

Mather SJ, Mckenzie AJ, Sosabowski JK, Morris TM, Watson SA. Selection of radiolabeled gastrin analogs for peptide receptor—targeted radionuclide therapy. J Nucl Med. 2007;48:615–22.CrossRefPubMedPubMedCentral

32.

Grob NM, Behe M, von Guggenberg E, Schibli R, Mindt TL. Methoxinine—an alternative stable amino acid substitute for oxidation-sensitive methionine in radiolabelled peptide conjugates. J Pept Sci. 2017;23:38–44.CrossRefPubMed

33.

Good S, Walter MA, Waser B, Wang X, Müller-Brand J, Béhé MP, et al. Macrocyclic chelator-coupled gastrin-based radiopharmaceuticals for targeting of gastrin receptor-expressing tumours. Eur J Nucl Med Mol Imaging. 2008;35:1868–77.CrossRefPubMed

34.

Kolenc Peitl P, Mansi R, Tamma M, Gmeiner-Stopar T, Sollner-Dolenc M, Waser B, et al. Highly improved metabolic stability and pharmacokinetics of indium-111-DOTA-gastrin conjugates for targeting of the gastrin receptor. J Med Chem. 2011;54:2602–9.CrossRefPubMed

35.

von Guggenberg E, Sallegger W, Helbok A, Ocak M, King R, Mather SJ, et al. Cyclic minigastrin analogues for gastrin receptor scintigraphy with technetium-99m: preclinical evaluation. J Med Chem. 2009;52:4786–93.CrossRefPubMed

36.

Laverman P, Béhé M, Oyen WJG, Willems PHGM, Corstens FHM, Behr TM, et al. Two technetium-99m-labeled cholecystokinin-8 (CCK8) peptides for scintigraphic imaging of CCK receptors. Bioconjug Chem. 2004;15:561–8.CrossRefPubMed

37.

von Guggenberg E, Behe M, Behr TM, Saurer M, Seppi T, Decristoforo C. ^99mTc-labeling and in vitro and in vivo evaluation of HYNIC- and ( Nα-His ) acetic acid-modified [D-Glu 1]-minigastrin. Bioconjugate Chem. 2004;15:864–71.

38.

Pfister J, Summer D, Rangger C, Petrik M, von Guggenberg E, Minazzi P, et al. Influence of a novel, versatile bifunctional chelator on theranostic properties of a minigastrin analogue. EJNMMI Res. 2015;5:74.CrossRefPubMedPubMedCentral

39.

Berman HM, Westbrook J, Feng Z, Gilliland G, Bhat TN, Weissig H, et al. The Protein Data Bank. Nucleic Acids Res. 2000;28:235–42.CrossRefPubMedPubMedCentral

40.

Dong M, Miller LJ. Direct demonstration of unique mode of natural peptide binding to the type 2 cholecystokinin receptor using photoaffinity labeling. Peptides. 2013;46:143–9.CrossRefPubMedPubMedCentral

41.

Dong M, Liu G, Pinon DI, Miller LJ. Differential docking of high-affinity peptide ligands to type A and B cholecystokinin receptors demonstrated by photoaffinity labeling. Biochemistry. 2005;44:6693–700.CrossRefPubMed

42.

Harikumar KG, Miller LJ. Fluorescence resonance energy transfer analysis of the antagonist- and partial agonist-occupied states of the cholecystokinin receptor. J Biol Chem. 2005;280:18631–5.CrossRefPubMed

43.

Escrieut C, De K, Clerc P, Niu F, Azema J, Masri B, et al. Distinct CCK-2 receptor conformations associated with β-arrestin-2 recruitment or phospholipase-C activation revealed by a biased antagonist. 2012;

44.

Marco E, Foucaud M, Langer I, Escrieut C, Tikhonova IG, Fourmy D. Mechanism of activation of a G protein-coupled receptor, the human cholecystokinin-2 receptor. J Biol Chem. 2007;282:28779–90.CrossRefPubMed

45.

Cawston EE, Lam PCH, Harikumar KG, Dong M, Ball AM, Augustine ML, et al. Molecular basis for binding and subtype selectivity of 1,4-benzodiazepine antagonist ligands of the cholecystokinin receptor. J Biol Chem. 2012;287:18618–35.CrossRefPubMedPubMedCentral

46.

Gupta AK, Varshney K, Singh N, Mishra V, Saxena M, Palit G, et al. Identification of novel amino acid derived CCK-2R antagonists as potential antiulcer agent: homology modeling, design, synthesis, and pharmacology. J Chem Inf Model 2013;53:176-87.

47.

Pettersen EF, Goddard TD, Huang CC, Couch GS, Greenblatt DM, Meng EC, et al. UCSF chimera—a visualization system for exploratory research and analysis. J Comput Chem. 2004;25:1605–12.CrossRefPubMed

48.

Steardo L, Knight M, Tamminga CA, Chase TN. Products of cholecystokinin (CCK)-octapeptide proteolysis interact with central CCK receptors. Neurosci Lett. 1985;54:319–25.CrossRefPubMed

49.

TILLEY JW, DANHO W, S -J SHIUEY, KULESHA I, SARABU R, SWISTOK J, et al. Structure activity of C-terminal modified analogs of Ac-CCK-7. Int J Pept Protein Res. 1992;39:322–36.CrossRefPubMed

50.

Corringer PJ, Weng JH, Ducos B, Durieux C, Boudeau P, Bohme A, et al. CCK-B agonist or antagonist activities of structurally hindered and peptidase-resistant Boc-CCK4 derivatives. J Med Chem. 1993;36:166–72.CrossRefPubMed

51.

Silvente-Poirot S, Escrieut C, Galès C, Fehrentz JA, Escherich A, Wank SA, et al. Evidence for a direct interaction between the penultimate aspartic acid of cholecystokinin and histidine 207, located in the second extracellular loop of the cholecystokinin B receptor. J Biol Chem. 1999;274:23191–7.CrossRefPubMed

52.

Marseigne I, Dor A, Begue D, Reibaud M, Zundel JL, Blanchard JC, et al. Synthesis and biological activity of CCK26-33-related analogs modified in position 31. J Med Chem. 1988;31:966–70.CrossRefPubMed

53.

Danho W, Tilley JW, Shiuey S-J, Kulesha I, Swistok J, Makofske R, et al. Structure activity studies of tryptophan30 modified analogs of Ac-CCK-7. Int J Pept Protein Res. 1992;39:337–47.CrossRefPubMed

54.

Rodriguez M, Bernad N, Galas M, Lignon M, Laur J, Aumelas A, et al. Synthesis and biological activities of cholecystokinin analogues substituted in position 30 by 3-(1-naphthyl)-l-alanine [Nal(1)] or 3-(2-naphthyl)-l-alanine [Nal(2)]. Eur J Med Chem. 1991;26:245–53.CrossRef

Title: Structural studies on radiopharmaceutical DOTA-minigastrin analogue (CP04) complexes and their interaction with CCK2 receptor
Authors: Piotr F. J. Lipiński
Piotr Garnuszek
Michał Maurin
Raphael Stoll
Nils Metzler-Nolte
Artur Wodyński
Jan Cz. Dobrowolski
Marta K. Dudek
Monika Orzełowska
Renata Mikołajczak
Publication date: 01-12-2018
Publisher: Springer Berlin Heidelberg
Published in: EJNMMI Research / Issue 1/2018
Electronic ISSN: 2191-219X
DOI: https://doi.org/10.1186/s13550-018-0387-3

Keynote webinar | Spotlight on sleep in brain health

Springer Medicine

Structural studies on radiopharmaceutical DOTA-minigastrin analogue (CP04) complexes and their interaction with CCK2 receptor

Abstract

Background

Results

Conclusions

Keynote webinar | Spotlight on sleep in brain health

Springer Medicine

Abstract

Background

Results

Conclusions

Please log in to get access to this content

Other articles of this Issue 1/2018

Prognostic value of simultaneous 18F-FDG PET/MRI using a combination of metabolo-volumetric parameters and apparent diffusion coefficient in treated head and neck cancer

In vivo confirmation of altered hepatic glucose metabolism in patients with liver fibrosis/cirrhosis by 18F-FDG PET/CT

Radiomics of the primary tumour as a tool to improve 18F-FDG-PET sensitivity in detecting nodal metastases in endometrial cancer

Reproducible quantification of cardiac sympathetic innervation using graphical modeling of carbon-11-meta-hydroxyephedrine kinetics with dynamic PET-CT imaging

Assessment of target-mediated uptake with immuno-PET: analysis of a phase I clinical trial with an anti-CD44 antibody

A semi-automatic technique to quantify complex tuberculous lung lesions on 18F-fluorodeoxyglucose positron emission tomography/computerised tomography images